NCT06278857 - SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2028

Conditions

Endometrial Cancer Stage IMmr DeficiencyEndometrioid Endometrial AdenocarcinomaImmune-related Adverse Event

Interventions

DRUG

Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI]

The dosing regimen follows standard clinical care protocol comprising of 4 cycles every 3-weeks, a rest period of 34 weeks followed by 3 cycles every 6 weekly for a total of 7 cycles.

Trial Locations (3)

2145

NOT_YET_RECRUITING

Westmead Hospital, Sydney

3000

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

4029

RECRUITING

Royal Brisbane and Women's Hospital, Brisbane